Woodstock Corp Has $2.96 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Woodstock Corp reduced its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 12.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,267 shares of the biopharmaceutical company's stock after selling 7,447 shares during the quarter. Woodstock Corp's holdings in Bristol-Myers Squibb were worth $2,956,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of BMY. Goldstone Financial Group LLC lifted its position in shares of Bristol-Myers Squibb by 6.1% in the 4th quarter. Goldstone Financial Group LLC now owns 4,824 shares of the biopharmaceutical company's stock worth $273,000 after acquiring an additional 279 shares during the period. KMG Fiduciary Partners LLC lifted its position in Bristol-Myers Squibb by 13.3% in the fourth quarter. KMG Fiduciary Partners LLC now owns 35,210 shares of the biopharmaceutical company's stock worth $1,992,000 after purchasing an additional 4,144 shares during the period. Decker Retirement Planning Inc. acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth $474,000. Cohen Investment Advisors LLC increased its holdings in Bristol-Myers Squibb by 2.6% in the 4th quarter. Cohen Investment Advisors LLC now owns 8,802 shares of the biopharmaceutical company's stock valued at $498,000 after buying an additional 221 shares during the period. Finally, Ritholtz Wealth Management raised its stake in shares of Bristol-Myers Squibb by 65.2% in the 4th quarter. Ritholtz Wealth Management now owns 39,389 shares of the biopharmaceutical company's stock valued at $2,228,000 after buying an additional 15,546 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, EVP Samit Hirawat purchased 1,830 shares of the firm's stock in a transaction dated Friday, November 1st. The stock was bought at an average price of $54.67 per share, with a total value of $100,046.10. Following the acquisition, the executive vice president now directly owns 62,109 shares of the company's stock, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the firm's stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on BMY shares. Truist Financial upped their target price on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Daiwa Capital Markets raised Bristol-Myers Squibb from a "neutral" rating to an "outperform" rating in a report on Wednesday, November 13th. Jefferies Financial Group raised Bristol-Myers Squibb from a "hold" rating to a "buy" rating and boosted their price target for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Sanford C. Bernstein assumed coverage on Bristol-Myers Squibb in a report on Thursday, October 17th. They set a "market perform" rating and a $56.00 price objective for the company. Finally, Leerink Partners raised shares of Bristol-Myers Squibb from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $55.00 to $73.00 in a report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $56.27.

Bristol-Myers Squibb Trading Down 0.0 %

Bristol-Myers Squibb stock traded down $0.03 during mid-day trading on Friday, hitting $56.35. The stock had a trading volume of 10,909,530 shares, compared to its average volume of 10,195,547. The stock has a 50-day simple moving average of $57.48 and a two-hundred day simple moving average of $51.82. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The stock has a market capitalization of $114.30 billion, a PE ratio of -15.70, a P/E/G ratio of 1.95 and a beta of 0.45. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.08.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. During the same quarter last year, the firm earned $2.00 EPS. The company's revenue for the quarter was up 8.4% on a year-over-year basis. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be given a $0.62 dividend. This is a positive change from Bristol-Myers Squibb's previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a dividend yield of 4.40%. The ex-dividend date is Friday, January 3rd. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently -69.08%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.